Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Insiders Buy Shares at AGCO and Texas Industries While Infinity Pharmaceuticals Sees a Major Sell-Off

By

Plus, a purchase at Navistar International.

PrintPRINT
Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside sales and purchases filed with the SEC on Tuesday, April 16, 2013.

Purchases: Mallika Srinivasan, a Director of agricultural equipment company AGCO Corporation (NYSE:AGCO), bought 80,373 shares of company stock for $3,917,866. Since April 1, she has purchased $78,444,979 worth of company stock. During that period, the stock's price has decreased by as much as 8.75%. The company announced today that its earnings call for first-quarter results will be held on April 30 at 10:00 a.m. EDT.

Bernard Lanigan, a Director of heavy construction materials supplier Texas Industries (NYSE:TXI), bought 8,000 shares of company stock for $476,215. The company operate in three segments, with cement, aggregates (sand, gravel, and crushed limestone), and specialty lightweight aggregates (ready-mix concrete). The stock's price has increased by 12.8% year-to-date; it has increased by 62.8% since this time last year. Lanigan is also the Chairman and CEO of Southeastern Asset Management, which as of December 31, 2012, owned 8,193,557 shares of TXI, about 28.82% of the company.

John Pope, a Director of Navistar International (NYSE:NAV), bought 6,370 shares of company stock for $199,270. Navistar manufactures commercial and military trucks, diesel engines, recreational vehicles, and parts for trucks and trailers. The company has been revamping its management lately, most recently announcing yesterday that Jack Allen would take the position of COO, the company's No. 2 executive. Last month, a former General Motors (NYSE:GM) executive, Troy Clarke, was announced as the new CEO and officially took the position yesterday. The company's stock price is up 45.15% year-to-date, but down 15.87% since this time last year.

Sales: Beacon Company sold 5,708,282 shares of drug discovery and development company Infinity Pharmaceuticals (NASDAQ:INFI) for $219,198,032. The company announced yesterday the closing of an underwritten secondary public offering of stock, having sold 11,416,565 shares at the price of $40 each. The other 5,708,283 shares not sold by Beacon were sold by Rosebay Medical Company L.P. Both companies sold their entire stake in Infinity Pharmaceuticals. The company's stock price is up 12.8% year-to date; it is up 210.13% since this time last year.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
DIR
AB
$3,917,866
2
DIR
B
$476,215
3
CEO,DIR,BO
JB*
$341,729
4
DIR
B
$199,270
5
DIR
B
$199,231
6
BO
B
$116,705
7
BO
B
$65,364
8
BO
JB*
$52,256
9
CB,CEO,BO
B
$46,249
10
BO
B
$37,597

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1
BO
JS*
$219,198,032
2
DIR
S
$30,720,000
3
DIR
AS
$4,167,438
4
BO
S
$2,800,662
5
CB,DIR,BO
S
$1,884,419
6
DIR
AS
$1,482,621
7
PR,CEO,DIR
AS
$1,466,111
8
DIR
AS
$1,379,379
9
CEO,DIR
AS
$1,103,950
10
DIR
AS
$843,600

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights:

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of "Profit From Legal Insider Trading."

Follow me on Twitter: @JoshWolonick and @Minyanville
No positions in stocks mentioned.
PrintPRINT
 
Featured Videos

WHAT'S POPULAR IN THE VILLE